- Home
- TSHA vs VRCA Comparison
TSHA vs VRCA Comparison
Compare TSHA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- VRCA
- Stock Information
- Founded
- TSHA 2019
- VRCA 2013
- Country
- TSHA United States
- VRCA United States
- Employees
- TSHA N/A
- VRCA N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- VRCA Health Care
- Exchange
- TSHA Nasdaq
- VRCA Nasdaq
- Market Cap
- TSHA 403.7M
- VRCA 363.1M
- IPO Year
- TSHA 2020
- VRCA 2018
- Fundamental
- Price
- TSHA $2.06
- VRCA $0.83
- Analyst Decision
- TSHA Strong Buy
- VRCA Buy
- Analyst Count
- TSHA 8
- VRCA 6
- Target Price
- TSHA $6.63
- VRCA $7.33
- AVG Volume (30 Days)
- TSHA 6.0M
- VRCA 767.2K
- Earning Date
- TSHA 11-13-2024
- VRCA 11-04-2024
- Dividend Yield
- TSHA N/A
- VRCA N/A
- EPS Growth
- TSHA N/A
- VRCA N/A
- EPS
- TSHA N/A
- VRCA N/A
- Revenue
- TSHA $9,915,000.00
- VRCA $9,210,000.00
- Revenue This Year
- TSHA N/A
- VRCA $123.42
- Revenue Next Year
- TSHA N/A
- VRCA $124.76
- P/E Ratio
- TSHA N/A
- VRCA N/A
- Revenue Growth
- TSHA N/A
- VRCA 187.45
- 52 Week Low
- TSHA $1.19
- VRCA $0.70
- 52 Week High
- TSHA $4.32
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- TSHA 55.32
- VRCA 34.37
- Support Level
- TSHA $1.19
- VRCA $0.83
- Resistance Level
- TSHA $2.63
- VRCA $0.94
- Average True Range (ATR)
- TSHA 0.24
- VRCA 0.13
- MACD
- TSHA 0.08
- VRCA -0.02
- Stochastic Oscillator
- TSHA 60.42
- VRCA 12.52
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.